Crystal structures of seven macrocyclic peptidomimetics bound to HIV protease reveal how circular peptide scaffolds can achieve potent antiviral activity with improved drug-like properties.
7 structures solvedHigh-resolution crystal structures reveal exactly how macrocyclic peptide drugs bind and inhibit HIV protease
What the researchers found
High-resolution crystal structures of seven macrocyclic HIV protease inhibitors revealed specific binding interactions, demonstrating how cyclic peptide scaffolds can achieve potent enzyme inhibition with improved drug properties.
Why it matters
HIV protease inhibitors are a cornerstone of AIDS treatment. Designing cyclic versions with better stability and bioavailability could improve existing drugs and inspire peptidomimetic approaches for other diseases.
How the study worked
X-ray crystallography study determining high-resolution structures of seven macrocyclic peptidomimetics complexed with HIV-1 protease. Structure-activity analysis correlated binding features with inhibitory potency.
What this study cannot tell us
Structural study focused on binding interactions, not clinical pharmacology. In-vitro potency may not predict in-vivo drug performance. Synthesis of macrocyclic compounds can be challenging at scale.
How to read the evidence
Preliminary evidence from structural biology providing detailed molecular insight into drug-target interactions, without in-vivo pharmacology data.
When this study was published
Published in 1999. Macrocyclic drug design has become a major pharmaceutical strategy, with several macrocyclic drugs now in clinical use for HIV and other diseases.
The bigger picture
The macrocyclic approach to drug design — converting linear peptides into circular ones — is now a major strategy in pharmaceutical development. This study provided early structural proof that this approach works for clinically important targets.
Questions still open
- Can these macrocyclic designs achieve oral bioavailability?
- Could the macrocyclic scaffold approach be applied to other protease targets?
- Which ring size and composition optimizes both potency and drug properties?
Common questions
What is a macrocyclic peptidomimetic?
How does this help fight HIV?
Read the original research
Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.
Biochemistry, 38(25), 7978-88
Citation
Martin, J L; Begun, J; Schindeler, A; Wickramasinghe, W A; Alewood, D; Alewood, P F; Bergman, D A; Brinkworth, R I; Abbenante, G; March, D R; Reid, R C; Fairlie, D P. (1999). Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.. Biochemistry, 38(25), 7978-88.